Cancer incidence and surveillance strategies in individuals with RASopathies

Area of Science:

• Genetics
• Oncology
• Pediatrics

Background:

• RASopathies are a group of genetic syndromes with shared molecular and clinical features.
• These syndromes stem from germline variants in RAS/MAPK pathway genes, leading to pathway activation.
• Common phenotypes include cardiac and neurologic issues, and a significantly elevated cancer risk.

Purpose of the Study:

• To review and synthesize current knowledge on cancer risk in RASopathies.
• To evaluate the effectiveness of existing cancer surveillance guidelines for specific RASopathies.
• To highlight the need for improved cancer risk estimates and refined surveillance strategies.

Main Methods:

• Review of retrospective studies and cohort data on cancer incidence in RASopathies.
• Analysis of established cancer surveillance protocols for Costello syndrome and Noonan syndrome.
• Synthesis of clinical and molecular data linking RAS/MAPK pathway variants to cancer phenotypes.

Main Results:

• Individuals with RASopathies exhibit elevated cancer incidence compared to the general population.
• Costello syndrome shows increased risk for solid tumors, necessitating abdominal ultrasound and urinalysis surveillance.
• Noonan syndrome presents an elevated risk for hematologic malignancies, requiring complete blood counts and splenic examination.

Conclusions:

• Cancer surveillance is crucial for managing RASopathies due to heightened cancer risks.
• Current surveillance guidelines require refinement based on updated cancer risk data.
• Improved risk stratification and surveillance recommendations will enhance patient outcomes in RASopathies.